Live Breaking News & Updates on நிதி மேலாண்மை இணை

Stay updated with breaking news from நிதி மேலாண்மை இணை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

I-Mab Appoints Ruyi He and Rong Shao to Board of Directors


Share this article
Share this article
SHANGHAI and GAITHERSBURG, Md., June 1, 2021 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that Dr. Ruyi He and Professor Rong Shao have been elected as members of the Company s board of directors. Dr. Ruyi He will serve on the compensation committee and Professor Shao will serve on the corporate governance committee both effective June 1, 2021.
We are honored to welcome Dr. He and Professor Shao to our board, and look forward to their wealth of industry experience and breadth of relationships as we transform into a fully integrated global biopharmaceutical company. Both Dr. He and Professor Shao are leading experts in their respective fields, and their appointments will further strengthen I-Mab s next phase of growth, said Dr. Jingwu Zang, Founder, Chairman and Director of I-Mab. ....

National Institutes Of Health , United States , Hong Kong , San Diego , Howard University Hospital , District Of Columbia , Emilie Wu , Rong Shao , Gigi Feng , Jingwu Zang , Jielun Zhu , Drug Administration Law , Shenyang Pharmaceutical University , National Institute Of Diabetes , Prnewswire The Company Nasdaq , China Medical University , Fund Management Co , Chinese Journal Of Health , China Pharmaceutical University , China Society For Drug Regulation , China Pharmaceutical Association , Drug Administration , Research Center , Piacente Group Inc , Exchange Commission , Remegen Inc ,

Manulife taps UBS veteran to oversee its China business


Manulife taps UBS veteran to oversee its China business
Print
Adrian Chen joined Manulife Investment Management in Shanghai as head of wealth and asset management for China effective March 1.
The position is new. Mr. Chen will focus on opportunities for Manulife in three areas: China s domestic fund business, where the firm has a 49% stake in Beijing-based Manulife TEDA Fund Management Co.; distributing Manulife s offshore capabilities to Chinese institutional and retail investors; and serving the country s fast-growing retirement market, a news release said Friday.
Mr. Chen is tasked with overseeing the day-to-day operations of Manulife Investment (Shanghai) Ltd. Co., the wholly foreign-owned enterprise which houses the firm s China institutional sales team, and working with its majority-owned life insurance joint venture, Shanghai-based Manulife-Sinochem Life Insurance Co. Ltd., to pursue opportunities in China s pension and retail wealth markets. ....

Lingrong Chen , Adrian Chen , Manulife Investment Shanghai Ltd , Manulife Sinochem Life Insurance Co , Fund Management Co , Manulife Investment Management , Beijing Based Manulife , Manulife Investment , Shanghai Based Manulife Sinochem Life Insurance , Investment Management , மனுளிபே முதலீடு ஷாங்காய் லிமிடெட் , நிதி மேலாண்மை இணை , மனுளிபே முதலீடு மேலாண்மை , பெய்ஜிங் அடிப்படையிலானது மனுளிபே , மனுளிபே முதலீடு , முதலீடு மேலாண்மை ,